Submit Manuscript  

Article Details

Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19

[ Vol. 16 , Issue. 1 ]


Milad Shirvaliloo*   Pages 55 - 57 ( 3 )


It is not unbeknownst to us that since the very onset of the COVID-19 outbreak, many patients from different age groups have suffered greatly, and in a remarkable number of cases, succumbed to their untimely demise as a result of infection with the novel coronavirus or SARS-CoV- -2. The elderly are perhaps the most vulnerable community, who stand at the pinnacle of morbidity and mortality rates due to contracting severe forms of COVID-19. Hopefully, based on the recent findings and the present evidence, there might be a number of medications that would possibly be of great prophylactic and therapeutic value to the elderly patients diagnosed with COVID-19. According to an interventional study, Thymosin α1 is arguably one such medication that has recently been indicated to be an effective therapeutic agent for inpatient management of lymphocytopenia and T cell exhaustion caused by COVID-19.


Thymosin α1, lymphocytopenia, T cells, COVID-19, SARS-CoV-2, immunoregulatory drug.


Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz

Graphical Abstract:

Read Full-Text article